Ocular jumps on plans to fast-track FDA filing for eye disease drug

Regeneron Pharmaceuticals

08/12/2025 15:23

Updates

** Shares of Ocular Therapeutix OCUL.O rise 27% to $15.91

** OCUL plans to submit a marketing application for its eye disease drug, Axpaxli, to treat wet age-related macular degeneration after one-year data from its ongoing late-stage trial, expected in the first quarter of 2026

** Wet AMD is a leading cause of vision loss in older adults, marked by abnormal blood vessel growth in the retina

     ** Company says the study is designed to show superiority over Regeneron's REGN.O Eylea and aligns with recent FDA guidance that a single, well-controlled trial may support approval

** Including session's moves, stock up 81.5% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))